Literature DB >> 28187521

The Role of FcRn in the Pharmacokinetics of Biologics in Patients With Multiple Myeloma.

J F M Jacobs1, D R Mould2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28187521     DOI： 10.1002/cpt.665

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

Review 1.  Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming.

Authors:  Diane R Mould; Richard N Upton; Jessica Wojciechowski; Becky L Phan; Stacy Tse; Marla C Dubinsky
Journal:  AAPS J       Date:  2018-06-14       Impact factor: 4.009

2.  Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.

Authors:  Hoai-Thu Thai; Nadia Gaudel; Marc Cerou; Geraldine Ayral; Jean-Baptiste Fau; Bernard Sebastien; Helgi van de Velde; Dorothée Semiond; Christine Veyrat-Follet
Journal:  Br J Clin Pharmacol       Date:  2021-11-26       Impact factor: 3.716

3.  Response to "The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma".

Authors:  Xu Steven Xu; Jordan M Schecter; Richard Jansson; Xiaoyu Yan
Journal:  Clin Pharmacol Ther       Date:  2017-07-29       Impact factor: 6.875

4.  Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.

Authors:  Ken Ogasawara; Kathryn Newhall; Stephen E Maxwell; Justine Dell'Aringa; Vitalina Komashko; Nurgul Kilavuz; Richard Delarue; Myron Czuczman; Lars Sternas; Shelonitda Rose; C L Beach; Steven Novick; Simon Zhou; Maria Palmisano; Yan Li
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.